C1 Esterase Inhibitor Deficiency: Clinical Trials

5 trials for C1 Esterase Inhibitor Deficiency, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 1 enrolling by invitation, 1 terminated. 3 Phase 2, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 23Completed 1, Enrolling by invitation 1, Terminated 1
Phase 32Completed 1, Enrolling by invitation 1

Follow C1 Esterase Inhibitor Deficiency: new trials by email Literature Review of C1 Esterase Inhibitor Deficiency trials Research Report on C1 Esterase Inhibitor Deficiency

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
Deucrictibant, Placebo - Hereditary Angioedema, Hereditary Angioedema Type I
Phase 3CompletedPharvaris Netherlands B.V.1342024-02-262025-11-21
Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema
deucrictibant - Hereditary Angioedema, Hereditary Angioedema Type I
Phase 2 / Phase 3Enrolling by invitationPharvaris Netherlands B.V.1502022-12-282026-07-21
Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II
Deucrictibant low dose, Deucrictibant high dose, Placebo - Hereditary Angioedema, Hereditary Angioedema Type I
Phase 2TerminatedPharvaris Netherlands B.V.342022-04-192026-08-17
Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema
Deucrictibant, Placebo - Hereditary Angioedema, Hereditary Angioedema Type I
Phase 2CompletedPharvaris Netherlands B.V.742021-02-032025-12-17
Biomarker for Hereditary AngioEdema Disease
C1 Esterase Inhibitor Deficiency, Angio Edema
CompletedCENTOGENE GmbH Rostock422018-08-202022-03-24

Narrower conditions

Angioedemas, Hereditary (5)  ·  Hereditary Angioedema Types I and II (5)  ·  Hereditary Angioedema Type III (3)  ·  Angioedema (1)

Broader conditions

Cardiovascular Diseases (5)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5)  ·  Genetic Diseases, Inborn (5)  ·  Hereditary Complement Deficiency Diseases (5)  ·  Hypersensitivity (5)  ·  Hypersensitivity, Immediate (5)  ·  Immune System Diseases (5)  ·  Immunologic Deficiency Syndromes (5)  ·  Primary Immunodeficiency Diseases (5)  ·  Skin Diseases (5)  ·  Skin Diseases, Vascular (5)  ·  Skin and Connective Tissue Diseases (5)  ·  Urticaria (5)  ·  Vascular Diseases (5)  ·  Angioedema (4)

Sponsors

Pharvaris Netherlands B.V. (4)  ·  CENTOGENE GmbH Rostock (1)

Countries

Poland (5)  ·  Bulgaria (4)  ·  Canada (4)  ·  Germany (4)  ·  Italy (4)  ·  United Kingdom (4)  ·  United States (4)  ·  Austria (3)  ·  Czechia (3)  ·  France (3)  ·  Hungary (3)  ·  Netherlands (3)  ·  Spain (3)  ·  Turkey (Türkiye) (3)  ·  Argentina (2)

Top investigators

Marc Riedl, MD (1)  ·  Marcus Maurer, Prof MD (1)  ·  Peter Bauer, MD (1)

Results publications

PMID 41865746, PMID 41865747, PMID 42849489

NIH funding

2023 (1)